Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
Every-8-Week shot could simplify PNH treatment
Disease control OngoingThis study tests the long-term safety of an experimental drug called OMS906 in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants receive OMS906 as an intravenous infusion every 8 weeks. The goal is to see if this dosing schedule is safe an…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental drug offered to stem cell transplant patients with rare blood disorder
Disease control APPROVED_FOR_MARKETINGThis program provides narsoplimab, an experimental drug, to patients who develop a serious blood clotting condition called thrombotic microangiopathy after a stem cell transplant. The goal is to offer treatment when no other options are available. Patients must have had a stem ce…
Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC